Literature DB >> 17033625

DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis.

Bettina Lorenz-Depiereux1, Murat Bastepe, Anna Benet-Pagès, Mustapha Amyere, Janine Wagenstaller, Ursula Müller-Barth, Klaus Badenhoop, Stephanie M Kaiser, Roger S Rittmaster, Alan H Shlossberg, José L Olivares, César Loris, Feliciano J Ramos, Francis Glorieux, Miikka Vikkula, Harald Jüppner, Tim M Strom.   

Abstract

Hypophosphatemia is a genetically heterogeneous disease. Here, we mapped an autosomal recessive form (designated ARHP) to chromosome 4q21 and identified homozygous mutations in DMP1 (dentin matrix protein 1), which encodes a non-collagenous bone matrix protein expressed in osteoblasts and osteocytes. Intact plasma levels of the phosphaturic protein FGF23 were clearly elevated in two of four affected individuals, providing a possible explanation for the phosphaturia and inappropriately normal 1,25(OH)2D levels and suggesting that DMP1 may regulate FGF23 expression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17033625      PMCID: PMC5942547          DOI: 10.1038/ng1868

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  15 in total

1.  Characterization of PHEX endopeptidase catalytic activity: identification of parathyroid-hormone-related peptide107-139 as a substrate and osteocalcin, PPi and phosphate as inhibitors.

Authors:  G Boileau; H S Tenenhouse; L Desgroseillers; P Crine
Journal:  Biochem J       Date:  2001-05-01       Impact factor: 3.857

2.  DMP1 depletion decreases bone mineralization in vivo: an FTIR imaging analysis.

Authors:  Yunfeng Ling; Hector F Rios; Elizabeth R Myers; Yongbo Lu; Jian Q Feng; Adele L Boskey
Journal:  J Bone Miner Res       Date:  2005-08-22       Impact factor: 6.741

3.  FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate.

Authors:  A E Bowe; R Finnegan; S M Jan de Beur; J Cho; M A Levine; R Kumar; S C Schiavi
Journal:  Biochem Biophys Res Commun       Date:  2001-06-22       Impact factor: 3.575

4.  Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23.

Authors:  K E White; G Carn; B Lorenz-Depiereux; A Benet-Pages; T M Strom; M J Econs
Journal:  Kidney Int       Date:  2001-12       Impact factor: 10.612

5.  Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: a model for impaired mineralization in X-linked rickets (HYP).

Authors:  Peter S N Rowe; Ian R Garrett; Patricia M Schwarz; David L Carnes; Eileen M Lafer; Gregory R Mundy; Gloria E Gutierrez
Journal:  Bone       Date:  2004-11-24       Impact factor: 4.398

6.  Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23.

Authors: 
Journal:  Nat Genet       Date:  2000-11       Impact factor: 38.330

7.  Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.

Authors:  Kenneth B Jonsson; Richard Zahradnik; Tobias Larsson; Kenneth E White; Toshitsugu Sugimoto; Yasuo Imanishi; Takehisa Yamamoto; Geeta Hampson; Hiroyuki Koshiyama; Osten Ljunggren; Koichi Oba; In Myung Yang; Akimitsu Miyauchi; Michael J Econs; Jeffrey Lavigne; Harald Jüppner
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

8.  Dual functional roles of dentin matrix protein 1. Implications in biomineralization and gene transcription by activation of intracellular Ca2+ store.

Authors:  Karthikeyan Narayanan; Amsaveni Ramachandran; Jianjun Hao; Gen He; Kyle Won Park; Michael Cho; Anne George
Journal:  J Biol Chem       Date:  2003-03-03       Impact factor: 5.157

9.  Bone morphogenetic protein-1/Tolloid-like proteinases process dentin matrix protein-1.

Authors:  Barry M Steiglitz; Melvin Ayala; Karthikeyan Narayanan; Anne George; Daniel S Greenspan
Journal:  J Biol Chem       Date:  2003-10-24       Impact factor: 5.157

10.  Evidence for the proteolytic processing of dentin matrix protein 1. Identification and characterization of processed fragments and cleavage sites.

Authors:  Chunlin Qin; Jan C Brunn; Richard G Cook; Ralph S Orkiszewski; James P Malone; Arthur Veis; William T Butler
Journal:  J Biol Chem       Date:  2003-06-17       Impact factor: 5.157

View more
  213 in total

Review 1.  Hereditary disorders of renal phosphate wasting.

Authors:  Amir S Alizadeh Naderi; Robert F Reilly
Journal:  Nat Rev Nephrol       Date:  2010-10-05       Impact factor: 28.314

Review 2.  The expanding family of hypophosphatemic syndromes.

Authors:  Thomas O Carpenter
Journal:  J Bone Miner Metab       Date:  2011-12-14       Impact factor: 2.626

Review 3.  Miscellaneous non-inflammatory musculoskeletal conditions. Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and αKlotho).

Authors:  Emily G Farrow; Erik A Imel; Kenneth E White
Journal:  Best Pract Res Clin Rheumatol       Date:  2011-10       Impact factor: 4.098

4.  Novel NaPi-IIc mutations causing HHRH and idiopathic hypercalciuria in several unrelated families: long-term follow-up in one kindred.

Authors:  Y Yu; S R Sanderson; M Reyes; A Sharma; N Dunbar; T Srivastava; H Jüppner; C Bergwitz
Journal:  Bone       Date:  2012-02-24       Impact factor: 4.398

5.  Ablation of systemic phosphate-regulating gene fibroblast growth factor 23 (Fgf23) compromises the dentoalveolar complex.

Authors:  E Y Chu; H Fong; F A Blethen; K A Tompkins; B L Foster; K D Yeh; K J Nagatomo; D Matsa-Dunn; D Sitara; B Lanske; R B Rutherford; M J Somerman
Journal:  Anat Rec (Hoboken)       Date:  2010-07       Impact factor: 2.064

6.  Inhibition of proprotein convertase SKI-1 blocks transcription of key extracellular matrix genes regulating osteoblastic mineralization.

Authors:  Jeff P Gorski; Nichole T Huffman; Sridar Chittur; Ronald J Midura; Claudine Black; Julie Oxford; Nabil G Seidah
Journal:  J Biol Chem       Date:  2010-11-12       Impact factor: 5.157

7.  Sustained Klotho delivery reduces serum phosphate in a model of diabetic nephropathy.

Authors:  Julia M Hum; Linda M O'Bryan; Arun K Tatiparthi; Erica L Clinkenbeard; Pu Ni; Martin S Cramer; Manoj Bhaskaran; Robert L Johnson; Jonathan M Wilson; Rosamund C Smith; Kenneth E White
Journal:  J Appl Physiol (1985)       Date:  2019-01-03

8.  Mineralizing enthesopathy is a common feature of renal phosphate-wasting disorders attributed to FGF23 and is exacerbated by standard therapy in hyp mice.

Authors:  Andrew C Karaplis; Xiuying Bai; Jean-Pierre Falet; Carolyn M Macica
Journal:  Endocrinology       Date:  2012-10-04       Impact factor: 4.736

9.  Overlapping functions of bone sialoprotein and pyrophosphate regulators in directing cementogenesis.

Authors:  M Ao; M B Chavez; E Y Chu; K C Hemstreet; Y Yin; M C Yadav; J L Millán; L W Fisher; H A Goldberg; M J Somerman; B L Foster
Journal:  Bone       Date:  2017-09-01       Impact factor: 4.398

Review 10.  The Causes of Hypo- and Hyperphosphatemia in Humans.

Authors:  Eugénie Koumakis; Catherine Cormier; Christian Roux; Karine Briot
Journal:  Calcif Tissue Int       Date:  2020-04-13       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.